

ESMO PRECEPTORSHIP PROGRAMME METASTATIC BLADDER AND KIDNEY CANCER

Multidisciplinary management, standards of care,
therapeutic targets and future perspectives

Zurich, Switzerland
3-4 April 2025

CO-CHAIRS Laurence Albiges, France
Viktor Grünwald, Germany

SPEAKERS Axel Bex, United Kingdom
Guillermo De Velasco, Spain
Patrizia Giannatempo, Italy
Yohann Loriot, France
Morgan Roupret, France
Cristina Suarez, Spain
Ursula Vogl, Switzerland

LEARNING OBJECTIVES

- To learn about fundamentals of molecular pathology and diagnosis as contributing factors to heterogeneity in bladder and kidney cancer
- To understand essentials in the assessment and multidisciplinary treatment of bladder and kidney cancer
- To learn about advances in treatment and novel targets in bladder and kidney cancer

Thursday, 3 April 2025

09:00-09:15 15'	Opening and welcome	Laurence Albiges, FR Viktor Grünwald, DE
15'	Welcome from ESMO - Objectives and scientific introduction	Laurence Albiges, FR Viktor Grünwald, DE
09:15-10:45 90'	SESSION 1 Bladder Cancer – Part I	Chairs: Yohann Loriot, FR Ursula Vogl, CH
15'	New treatments and approaches to NMIBC: What the oncologist needs to know	Morgan Roupret, FR
20'	Neoadjuvant treatments for MIBC	TBC
15'	Summary of adjuvant therapies for MIBC	Patrizia Giannatempo, IT
10'	Conservative approach in MIBC	TBC
15'	Biomarkers in perioperative bladder cancer	Yohann Loriot, FR
15'	Q&A	All
10:45-11:15	Coffee break	

11:15-12:45 90'	SESSION 2 Bladder Cancer – Part II	Chairs: Patrizia Giannatempo, IT Viktor Grünwald, DE
15'	First line treatment in advanced bladder cancer	TBC
15'	Second line and beyond in advanced bladder cancer	Yohann Lorient, FR
15'	Approaches to upper tract UC	Morgan Roupret, FR
15'	Q&A	All
30'	Participants clinical case discussion (3x10')	Faculty

12:45-13:45	Lunch
--------------------	--------------

13:45-15:10 85'	SESSION 3 Renal Cancer – Part I	Chairs: Laurence Albiges, FR Viktor Grünwald, DE
10'	Is there a role for nephrectomy in advanced disease?	Axel Bex, NL
10'	Is there a role for neoadjuvant treatment in RCC?	Axel Bex, NL
10'	Oligometastatic disease management	Guillermo De Velasco, ES
15'	Q&A	All
40'	Participants clinical case discussion (4x10')	Faculty

15:10-15:40	Coffee Break
--------------------	---------------------

15:40-17:15 95'	SESSION 4 Debate around adjuvant therapy for RCC	Chairs: Guillermo De Velasco, ES TBC
15'	Summary of adjuvant therapies for RCC	Cristina Suarez, ES
10'	Adjuvant treatment selection for localised RCC	Guillermo De Velasco, ES
10'	Surgeon point of view: Assessing the risk of relapse	Axel Bex, NL
15'	Treatment after progression on adjuvant therapy in renal carcinoma	Ursula Vogl, CH
15'	Q&A	All
30'	Participants clinical case discussion (3x10')	Faculty

19:30	Dinner
--------------	---------------

Friday, 4 April 2025

09:00-10:20 80'	SESSION 5 Renal Cancer – Part II	Chairs: Guillermo De Velasco, ES Ursula Vogl, CH
20'	Debate: Immune combinations or VEGF/PD1 inhibition as 1st line therapy for advanced clear cell RCC - Immune combinations - VEGF/PD1 inhibition	Laurence Albiges, FR Viktor Grünwald, DE
10'	Individualized therapy in frontline	Laurence Albiges, FR
15'	Second line and beyond in RCC	TBC
20'	Biology and treatment of non-clear RCC	Cristina Suarez, ES
15'	Q&A	All
10:20-10:50	Coffee break	
10:50-12:15 85'	SESSION 6 Focus on toxicity and duration of therapy	Chairs: Laurence Albiges, FR TBC
15'	Can we stop targeted therapy, immune therapy?	Viktor Grünwald, DE
15'	All you need to know on ADC toxicity management	Ursula Vogl, CH
10'	All you need to know on FGR inhibitor toxicity management	Patrizia Giannatempo, IT
15'	Q&A	All
30'	Participants clinical case discussion (3x10')	Faculty
12:15-12:25 10'	Conclusion and farewell	Laurence Albiges, FR Viktor Grünwald, DE
12:25-13:25	Lunch	

Note: Each 10 minute slot for participant clinical case discussion includes a 5' case presentation and a 5' Q&A / discussion